SITC 2023 | Decoy-resistant IL-18 plus anti-CTLA-4 blockade for renal cell carcinoma

David Schoenfeld, MD, PhD, Yale School of Medicine, New Haven, CT, provides an overview of his preclinical studies using decoy-resistant IL-18 (DR-18) in treating renal cell carcinoma. Mouse models of the disease were used and DR-18 was combined with single and dual anti-PD-1 and anti-CTLA-4 blockade agents; combination therapy with anti-CTLA-4 blockade provided significant antitumor activity and prolonged survival in the murine models. Dr Schoenfeld states there was no additional benefit with anti-PD-1 or triple therapy and plans to conduct further preclinical studies to assess the treatments’ mechanism of action and potentially early-phase trials. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.